Researchers from Nagoya University in Japan have developed a groundbreaking synthesis technology for producing high purity, fully chemically-synthesized mRNA.

This innovative method bypasses slow enzymatic reactions typically involved in mRNA production, significantly shortening the production process and enabling faster vaccine development.

Concerns about mRNA production, particularly regarding purity and speed, have been effectively addressed by this new synthesis method.

The research team introduced a novel phosphorylation reagent with a nitrobenzyl group, enhancing the mRNA's hydrophobicity and improving purification processes.

Using reverse-phase high-performance liquid chromatography, the team successfully separated pure RNA from impurities, ensuring high-quality mRNA.

In addition to linear mRNA, the team also created pure circular mRNA, which is resistant to degradation and offers longer-lasting medicinal effects.

This advancement allows for quicker responses to viral outbreaks and emerging diseases, potentially mitigating future infections.

The study's findings were published in the journal Nucleic Acids Research on October 17, 2024, highlighting the significance of this research.

mRNA technology gained prominence during the COVID-19 pandemic and is expected to play a crucial role in treating genetic disorders and other emerging illnesses.

Future applications of this technology may include developing new mRNA vaccines targeting cancer antigens and genetic diseases.

This breakthrough in mRNA production could revolutionize RNA drug discovery and expand the range of mRNA-based treatments.

Current mRNA derived from 5'-monophosphorylated RNA risks contamination and can trigger strong immune responses, increasing the risk of side effects.